Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
2Customers
1Debt Items
0Related Chains
Source-Backed Evidence Depth
XBiotech Inc. (XBIT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
4Distinct source URLs
6High confidence
0.813Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
XBiotech Inc. Suppliers
Ticker
Name
Confidence
Evidence
THIRD-PARTY-SERVICE-PROVIDERS
THIRD-PARTY-SERVICE-PROVIDERS
92%
Clinical Trial Accruals Expense accruals related to clinical trials are based on actual services received and efforts expended pursuant to contracts with third party service providers which conduct a…
WHITLEY-PENN
WHITLEY-PENN
92%
In connection with the audit of the 2025 and 2024 financial statements, the Company entered into an engagement agreement with Whitley Penn which sets forth the terms by which Whitley Penn will perfor…
VENDORS
VENDORS
90%
The Company accrues costs based on the actual services rendered in the period over which services were performed and the level of effort expended in each period based upon patient enrollment, clinica…
JANSSEN-BIOTECH-INC
JANSSEN-BIOTECH-INC
85%
The Company accrues costs based on the actual services rendered in the period over which services were performed and the level of effort expended in each period based upon patient enrollment, clinica…
LONZA-SALES-AG
LONZA-SALES-AG
75%
Licensing Agreement dated January 16, 2015 between XBiotech USA, Inc. and Lonza Sales AG
SOUTH-TEXAS-BLOOD-TISSUE-CENTER
SOUTH-TEXAS-BLOOD-TISSUE-CENTER
75%
Research and Collaboration Agreement dated December 15, 2014 by and between XBiotech USA, Inc. and the South Texas Blood & Tissue Center
XBiotech Inc. Customers
Ticker
Name
Confidence
Evidence
JANSSEN-BIOTECH-INC
JANSSEN-BIOTECH-INC
62%
revent fraud due to a failure to maintain effective internal control over financial reporting could cause shareholders to lose confidence in our financial and other public reporting. Risks Related to…
TRUST-COMPANY-LLC
TRUST-COMPANY-LLC
62%
24. 19 We will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research an…
XBiotech Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
XBIT-DEBT-13642
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-09-30.
XBiotech Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for XBiotech Inc..
XBiotech Inc. Ownership
Holder
Name
Confidence
Evidence
XBIT-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 42 tracked holders.
XBiotech Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
